Connect with us

News

Breath-based cancer test begins clinical trials in the UK

Published

on

The Cancer Research UK Cambridge Center has begun clinical trials for Cambridge-based Owlstone Medical’s Breath Biopsy® technology, a breathalyzer-type test that analyzes patients’ exhalations for biomarkers indicative of cancer. Samples from 1500 people, to include healthy participants as controls, will be used to determine whether the types of breath molecules assessed can positively identify both the presence of cancer and its type. The earlier cancer can be detected, the better the potential outcome for patients. Thus, noninvasive testing technology like Breath Biopsy® would be a very useful tool in cancer treatment.

The Breath Biopsy® test will search for what are called volatile organic compounds (VOCs), i.e., emissions triggered by cellular metabolic processes that enter the bloodstream. These act as biomarkers for cancer due to changes the disease makes to the body or made to the cancer growth itself. For example, during tumor growth, gene or protein changes can damage cell membranes and then release molecular byproducts specific to that type of tumor, VOCs, which are circulated in the lungs and exhaled. Normal human breath contains hundreds of VOCs from the body’s regular metabolic processes; however, certain types have been specifically linked to cancers, and researchers have been working to narrow the parameters to make clinically-useful tests, as is being done with Owlstone’s technology.

An overview of the VOC process in the body. | Credit: Owlstone Medical.

Early detection of cancer is one of the most significant tools that can impact its lethality, namely because most cancers aren’t found until they are at an advanced stage. Certain cancers, such as ovarian, lung, pancreatic, and colorectal, are hard to detect in their early stages, making survival rates low from the progression at the time of discovery. Also, tests for the presence of cancers are often invasive and expensive. Tools for accurate breath analysis identifying specific cancer biomarkers would provide significant improvement on both of these counts.

According to the National Cancer Institute, an estimated 1,735,350 new cases of cancer were diagnosed in 2018 in the United States, and 609,640 people died from the disease. Worldwide, that number is around 9 million per year. Statistics like these make the field of cancer research ripe for opportunities to address its numerous challenges with emerging and developing technologies.

Biotech has embraced cancer research and treatment as well as other fields not traditionally geared towards biological research. For example, artificial intelligence is aiding in cancer identification and prediction. Of further interest, genetic engineering is addressing environmental toxins known to cause cancer, and 3D printing is even being used in space to assess radiation’s effects on living tissue, a known factor in skin cancers. The push towards putting more humans in space will continue to expand the knowledge base in this area as science by NASA and similar national agencies and partners explore these issues as they relate to off-planet travel.

Advertisement

Accidental computer geek, fascinated by most history and the multiplanetary future on its way. Quite keen on the democratization of space. | It's pronounced day-sha, but I answer to almost any variation thereof.

Advertisement
Comments

News

Nvidia CEO Jensen Huang regrets not investing more in Elon Musk’s xAI

The CEO stated that Nvidia is already an investor in xAI, but he wished he had given the artificial intelligence startup more money.

Published

on

Credit: Elon Musk/X

Nvidia CEO Jensen Huang revealed that one of his investment regrets is not putting more money into Elon Musk’s artificial intelligence startup, xAI. 

Speaking in a CNBC interview, Huang said Nvidia is already an investor in xAI but wished he had given the artificial intelligence startup more money. This was due to Musk’s record of building transformative companies such as Tesla and SpaceX.

A new wave of transformative AI firms

Huang said he’s very excited about xAI’s latest financing round. He described Musk’s company as part of a powerful new generation of AI developers, alongside OpenAI and Anthropic. that are reshaping the computing landscape.

“I’m super excited about the financing opportunity they’re doing. The only regret I have about xAI, we’re an investor already, is that I didn’t give him more money. You know almost everything that Elon’s pat of, you really want to be part of as well,” the Nvidia CEO stated.

The CEO also clarified Nvidia’s investment in xAI, revealing that Elon Musk had offered the investment opportunity to the chipmaker. “He (Musk) gave us the opportunity to invest in xAI. I’m just delighted by that,” Huang stated.

Advertisement

AI investment boom

Huang contrasted today’s AI-driven economy with the early days of the internet. “Back then, all the internet companies combined were maybe $30 or $40 billion in size,” he said. “If you look at the hyperscalers now, that’s about $2.5 trillion of business already operating today.”

He also stated that the ongoing shift from CPU-based computing to GPU-powered generative AI represents a “multi-trillion-dollar buildout” that Nvidia is looking to support. Huang added that every Nvidia engineer now works with AI coding assistants such as Cursor, which he called his “favorite enterprise AI service,” and it has led to a major productivity boost across the company.

Watch Nvidia CEO Jensen Huang’s CNBC interview in the video below.

Continue Reading

Investor's Corner

Stifel raises Tesla price target by 9.8% over FSD, Robotaxi advancements

Stifel also maintained a “Buy” rating for the electric vehicle maker.

Published

on

Credit: Tesla China

Investment firm Stifel has raised its price target for Tesla (NASDAQ:TSLA) shares to $483 from $440 over increased confidence in the company’s self-driving and Robotaxi programs. The new price target suggests an 11.5% upside from Tesla’s closing price on Tuesday.

Stifel also maintained a “Buy” rating despite acknowledging that Tesla’s timeline for fully unsupervised driving may be ambitious.

Building confidence

In a note to clients, Stifel stated that it believes “Tesla is making progress with modest advancements in its Robotaxi network and FSD,” as noted in a report from Investing.com. The firm expects unsupervised FSD to become available for personal use in the U.S. by the end of 2025, with a wider ride-hailing rollout potentially covering half of the U.S. population by year-end.

Stifel also noted that Tesla’s Robotaxi fleet could expand from “tiny to gigantic” within a short time frame, possibly making a material financial impact to the company by late 2026. The firm views Tesla’s vision-based approach to autonomy as central to this long-term growth, suggesting that continued advancements could unlock new revenue streams across both consumer and mobility sectors.

Tesla’s FSD goals still ambitious

While Stifel’s tone remains optimistic, the firm’s analysts acknowledged that Tesla’s aggressive autonomy timeline may face execution challenges. The note described the 2025 unsupervised FSD target as “a stretch,” though still achievable in the medium term.

Advertisement

“We believe Tesla is making progress with modest advancements in its Robotaxi network and FSD. The company has high expectations for its camera-based approach including; 1) Unsupervised FSD to be available for personal use in the United States by year-end 2025, which appears to be a stretch but seems more likely in the medium term; 2) that it will ‘probably have ride hailing in probably half of the populations of the U.S. by the end of the year’,” the firm noted.

Continue Reading

News

Tesla Cybertruck gets Full Self-Driving v14 release date, sort of

Published

on

Tesla Cybertruck owners are wondering when they will get access to the company’s Full Self-Driving version 14.1 that rolled out to other owners today for the first time.

Cybertruck owners typically receive Full Self-Driving updates slightly later than other drivers, as the process for the all-electric pickup is different. It is a larger vehicle that requires some additional attention from Tesla before FSD versions are rolled out, so they will be slightly delayed. CEO Elon Musk said the all-wheel steering technically requires a bit more attention before rollout as well.

After some owners got access to the v14.1 Full Self-Driving suite this morning, Cybertruck owners sought out a potential timeframe for when they would be able to experience things for themselves.

Tesla owners show off improvements with new Full Self-Driving v14 rollout

They were able to get an answer from Ashok Elluswamy, Tesla’s Head of AI, who said:

“We got you. Coming soon.”

The release of FSD v14.1 for Cybertruck will not be tempered, either. Elluswamy then confirmed that Tesla would be rolling out the full-featured FSD v14 for the pickup, meaning it would be able to reverse and park itself, among other features.

Elluswamy said it would be capable of these features, which were void in other FSD releases for Cybertruck in the past.

Tesla’s rollout of FSD v14.1 brings several extremely notable changes and improvements to the suite, including more refined operation in parking garages, a new ability to choose parking preferences upon arriving at your destination, a new driving mode called “Sloth,” which is even more reserved than “Chill,” and general operational improvements.

Those who were lucky enough to receive the suite have already started showing off the improvements, and they definitely seem to be a step up from what v13’s more recent versions were capable of.

CEO Elon Musk called v14 “sentient” a few weeks back, and it seems that it is moving toward that. However, he did state that additional releases with more capabilities would be available in the coming weeks, but many owners are still waiting for this first version.

Continue Reading

Trending